Related Experiment Video

Updated: Aug 15, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.2K

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

Ming Yi1,2, Tianye Li3, Mengke Niu1

  • 1Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Frontiers in Immunology
|January 5, 2023
PubMed

Insights

Transforming growth factor-β (TGF-β) signaling promotes cancer immune evasion and resistance to immune checkpoint inhibitors (ICI). Blocking TGF-β with targeted therapies can overcome this resistance, improving cancer immunotherapy outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Transforming growth factor-β (TGF-β) signaling is crucial for normal physiological processes.
  • Dysregulated TGF-β signaling contributes to various diseases, notably cancer.
  • TGF-β influences the tumor microenvironment (TME) and immune cell behavior.

Purpose of the Study:

  • To review the role of TGF-β in cancer immune evasion.
  • To explore the association between TGF-β signaling and resistance to immune checkpoint inhibitors (ICI).
  • To discuss the therapeutic potential of targeting TGF-β in cancer immunotherapy.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of TGF-β's impact on the tumor microenvironment.
  • Evaluation of TGF-β blockade strategies in combination with ICI.

Main Results:

  • Hyperactive TGF-β signaling is linked to resistance to ICI therapy.
  • TGF-β blockade demonstrates synergy with ICI, overcoming treatment resistance.
  • Targeted TGF-β therapies show promise for enhancing cancer immunotherapy.

Conclusions:

  • TGF-β signaling is a key mechanism for cancer immune evasion.
  • Targeting TGF-β represents a promising strategy to improve the efficacy of cancer immunotherapy, particularly for ICI-resistant tumors.
Keywords:
PD-1PD-L1TGF-βbispecific antibodycancer biotherapycancer immunotherapytumor microenvironment

More Related Videos

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

12.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
622